Nachrichten zur AstraZeneca PLC Aktie

FTSE 100 climbs 1 points to 8,154 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 climbs 12 points to 8,166 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 drops 40 points to 8,114 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 drops 23 points to 8,130 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 drops 70 points to 8,084 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 climbs 3 points to 8,156 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 climbs 19 points to 8,173 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

…

AstraZeneca lifts full-year outlook on upbeat demand for therapies…

AstraZeneca 25 July 2024 H1 and Q2 2024 results Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core…

© Foto: Sven Hoppe/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im…

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of…

Is AstraZeneca set for another upgrade: ... read preview BT has had a tough first half according to one leading City firm,…

Eine wahren Datenflut erwartet uns am DonnerstagHeute stehen zahlreiche Unternehmensberichte an, darunter die Halbjahreszahlen von Audi, Hermes, Roche und AstraZeneca.…

Sales of AstraZenecas (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new…

…

AstraZenecas (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several…

15 July 2024 Acquisition of Amolyt Pharma completed AstraZeneca today announced the successful completion of theacquisition (https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html) of Amolyt Pharma, a clinical-stage biotechnology company focused…

LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company…

Todays Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and…

SmartCella Holding AB (“SmartCella”) today announces a new share issue raising approximately EUR 50 million to accelerate growth and support…

The European Commission approves AstraZenecas (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on…

The CHMP recommends approval of AstraZenecas (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on…

1 July 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

…

The Global Food Allergy Treatment Market Size was Valued at USD 5.67 Billion in 2023 and the Worldwide Food Allergy…

FDA rejects Merck (MRK) and AbbVies (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.…

Data from a late-stage study shows that treatment with AstraZenecas (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery…

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…

…

…

BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the formers artificial...…

25 June 2024 Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by…

25 June 2024 Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA…

LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat Roche nach Gesprächen mit einer einflussreichen Person aus einem der größten…

LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat Novartis nach Gesprächen mit einer einflussreichen Person aus einem der größten…

LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat Astrazeneca nach Gesprächen mit einer einflussreichen Person aus einem der größten…

The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…

FDA approves Mercks (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVies (ABBV) Skyrizi and AstraZenecas (AZN)…

The Global Anal Fissure Treatment Market Size was Valued at USD 1161.3 Million in 2023 and the Worldwide Anal Fissure…

The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical development Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) is…

The European Commission approves AstraZenecas (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.…

AstraZenecas (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to…

…

17 June 2024 Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer Approval based on DUO-E…

The FDA approves AstraZenecas (AZN) Imfinzi in combination with chemotherapy for treating mismatch repair deficient advanced/recurrent endometrial cancer based on…

…

…

Insmed retains rights to brensocatib after talks with AstraZeneca end…

Following the label expansion, AstraZenecas (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and…